Table 3.
Laboratory assessments and anti-hepatitis C virus treatments administered to patients with hepatitis C virus infection, and the responses to treatment n (%)
| HCV (n = 1406) | HCV and HBV (n = 42) | |
| Laboratory assessments: | ||
| HCV PCR positive1 | 1366/1375 (99.3) | 38/40 (95.0) |
| ALT abnormal2 | 575 (40.9) | |
| AST abnormal2 | 499 (35.5) | |
| AFP abnormal | 86/486 (17.7) | |
| Received antiviral treatment | 936 (66.6) | 22 (52.4) |
| Number of treatments | (n = 936) | (n = 23) |
| First | 751 (80.2) | 20 (87.0) |
| Second | 140 (15.0) | 3 (13.0) |
| Third | 45 (4.8) | 0 |
| Antiviral agents used in first-time antiviral treatments | (n = 750) | (n = 20) |
| Interferon (IFN) | 232 (30.9) | 5 (25.0) |
| PEG-IFN | 514 (68.5) | 15 (75.0) |
| Ribavirin | 702 (93.6) | 15 (75.0) |
| Duration of completed treatment, months (median, range) | (n = 277) | (n = 3) |
| 11.8 (0.1-139) | 11.9 (5-11.9) | |
| Responses to treatment3 | ||
| Quick response4 | 125/425 (29.4) | 4/10 (40.0) |
| Early response5 | 126/349 (36.1) | 2/6 (33.3) |
| Response at end of treatment6 | 38/276 (13.8) | 2/5 (40.0) |
| Sustained response7 | 24/121 (19.8) | 0 |
| No response | 20/276 (7.2) | 0 |
Results were unknown or unchecked for 2.2% of patients;
Results were unknown or unchecked for 10.8%-18.4% of patients;
Excludes patients in whom treatment was terminated early and patients not yet assessed due to ongoing treatment;
Quick response (HCV RNA negative on PCR after 4 wk of treatment): calculated in patients who had received at least 4 wk therapy;
Early response (HCV RNA negative on PCR negative or decreased by ≥ 2 log10 (IU/mL) after 12 wk of treatment): calculated in patients who had received at least 12 wk therapy;
Response rate at end of treatment: the proportion of the patients who had received at least 24 wk therapy achieved response;
Sustained response: patients who had a sustained response for at least 24 wk after completing therapy. AFP: α-Fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PCR: Polymerase chain reaction; PEG-IFN: Pegylated interferon.